Trial Profile
Phase II Study of AZD2171 (NSC 732208) in Patients With Malignant Mesothelioma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Cediranib (Primary)
- Indications Malignant-mesothelioma
- Focus Therapeutic Use
- 23 Aug 2012 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
- 07 Mar 2012 Actual end date (Sep 2010) added as reported by ClinicalTrials.gov.
- 07 Mar 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.